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Abstract
Background: Differences in plasma and whole blood expression microRNAs (miRNAs) in patients with an 
acute coronary syndrome (ACS) have been determined in both in vitro and in vivo studies. Although most circulating 
miRNAs are located in the cellular components of whole blood, little is known about the miRNA profiles of whole blood 
subcomponents, including plasma, platelets and leukocytes in patients with myocardial ischemia. 
Methods: Thirteen patients with a ST-segment-elevation (STEMI) or non-ST-segment elevation (NSTEMI) 
myocardial infarction were identified in the University of Massachusetts Medical Center Emergency Department (ED) 
or cardiac catheterization laboratory between February and June of 2012. Whole blood was obtained from arterial 
blood samples at the time of cardiac catheterization and cell-specific miRNA profiling was performed. Expression of 
343 miRNAs was quantified from whole blood, plasma, platelets, and peripheral blood mononuclear cells using a high-
throughput, quantitative Real-Time polymerase-chain reaction system (qRT-PCR). 
Results: MiRNAs associated with STEMI as compared to NSTEMI patients included miR-25-3p, miR-221-3p, 
and miR-374b-5p. MiRNA 30d-5p was associated with plasma, platelets, and leukocytes in both STEMI and NSTEMI 
patients; miRNAs 221-3p and 483-5p were correlated with plasma and platelets only in NSTEMI patients. 
Conclusions: Cell-specific miRNA profiles differed between patients with STEMI and NSTEMI. The miRNA 
distribution is also unique amongst plasma, platelets, and leukocytes in patients with ischemic heart disease or 
ACS. Our findings suggest unique miRNA profiles among the circulating subcomponents in patients presenting with 
myocardial ischemia.
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Introduction
Up to 10 million Americans report to an Emergency Department 
(ED) for chest pain yearly and this number is expected to climb 
with continued aging of the United States (U.S.) population [1]. The 
substantial number of emergent hospitalizations for acute coronary 
syndrome (ACS), including ST-elevation myocardial infarction 
(STEMI), Non ST-elevation myocardial infarction (NSTEMI), and 
unstable angina (UA), represents a significant financial strain to 
both patients and the healthcare system [2,3]. This burden could be 
ameliorated, and more efficient treatment administered, if a more 
rapid, sensitive, and specific biomarker could differentiate between 
the spectrum of ACS (i.e. STEMI, NSTEMI, and UA) as well as 
differentiate from other less concerning causes of chest pain, such as 
gastroesophageal reflux (GERD) [4]. 
MiRNA profiles have been described from whole blood of patients 
with an acute coronary syndrome [5,6]. Although previous studies have 
noted miRNAs specifically in the plasma of patients with myocardial 
ischemia, additional information is required to further understand 
the miRNA species in whole blood subcomponents, such as plasma, 
platelets and leukocytes. However, by examining circulating blood 
subcomponents, important biomarkers unique to ACS may be identified. 
For example, miRNAs may be ideal biomarkers for accelerating the 
diagnosis of MI in emergency department patients [7,8]. 
Differences in miRNA expression patterns in coronary artery 
disease (CAD), acute coronary syndrome (ACS) and microparticles 
(MP) have been previously investigated in both in vitro and in 
vivo models [9]. Previous studies have demonstrated differences in 
inflammatory kinetics between STEMI and NSTEMI patients [10]. 
However, little else is known about the miRNA profiles of circulating 
blood pools, platelets, and lymphocytes in patients within STEMI and 
NSTEMI. Therefore, the goal of this study was twofold: 1) to investigate 
if miRNA expression differed between patients presenting with STEMI 
and NSTEMI in a Central Massachusetts academic setting and 2) to 
describe the miRNA expression profiles of patients with an ACS further 
stratified by circulating subcomponents, including plasma, platelets, 
and leukocytes. 
Materials and Methods
Participant recruitment
102 patients presenting with an ACS were identified in 
the University of Massachusetts Medical Center ED or cardiac 
catheterization laboratory between February and June of 2012. Of the 
102 patients screened for inclusion, 13 fulfilled study inclusion criteria 
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for myocardial infarction, including both NSTEMI and STEMI [11,12]. 
Delayed, written informed consent was obtained from all enrollees after 
they were clinically stabilized. This study was approved by the University 
of Massachusetts Institutional Review Board (Docket H:14125).
Sample acquisition and handling
All participants underwent phlebotomy at the time of their cardiac 
catheterization procedure. 10 milliliters of arterial blood was obtained 
from a radial or femoral access site and transferred in a sterile fashion 
into PAXgene (Qiagen, CA), CPT (Becton-Dickenson, NJ), and 
ethylenediaminetetraacetic acid (EDTA) tubes. Samples were placed 
immediately on ice and then taken within 10 minutes to the study 
laboratory.
RNA isolation
Total RNA including small RNA and miRNAs isolated from plasma 
samples by using miRNeasy kit (Qiagen Valencia, CA) 100 µl plasma 
and 700 µl RLT solution mixed and incubated at room temperature 
for 10 minutes then isolation performed according to the protocol 
provided with the kit. Isolated RNA samples were stored at -80°C until 
cDNA reaction.
Reverse transcription reaction
Isolated RNAs were reverse-transcribed into cDNA in 5 μl final 
reaction volumes using TaqMan MicroRNA Reverse Transcription 
Kit (Applied Biosystems, Foster City, CA, USA). All reactions 
were performed as specified in the manufacturers protocol (except 
modification in final volume): 2 μl total RNA were added to 3 μl of 
the RT reaction mix (MegaPlex RT Primers 10X, dNTPs with dTTP 
100mM, MultiScribe Reverse Transcriptase 50 U/μl, 10X RT Buffer, 
MgCl2 25 mM, RNase Inhibitor 20 U/μl and Nuclease-free water). 
Reverse transcription was performed using 384 well Thermal Cycler 
(Veriti 384, Applied Biosystems, Foster City, CA, USA). 343 cardiac 
specific microRNAs were selected as previously described (The SABRe 
CVD Initiative; dbGaP Study Accession: phs000007.v18.p7). Reaction 
conditions were: 16°C for 120 sec, 42°C for 60 sec, 50°C for 1 sec, and 
these three steps repeated for 40 cycles and 85°C for 300 sec and 4°C for 
hold until further processing or storage. cDNA samples were kept at 
-80°C until Real-Time PCR analysis.
Preamplification
A preamplification reaction was performed after the reverse 
transcription using the TaqMan PreAmp Master Mix 2X (Applied 
Biosystems, Foster City, CA, USA) as well as the MegaPlex Human 
PreAmp Primer Pools Set v3.0 (Applied Biosystems, Foster City, CA, 
USA). All reactions were performed as specified in the protocols of the 
manufacturer. Two μl of 1:5 diluted Reverse Transcription products were 
added to 3 μl of the PreAmplification mixture. The reaction volume was 
5 μl miRNA TaqMan PreAmp Thermal Protocol was performed using 
384 well Thermal Cycler (Veriti 384, Applied Biosystems, Foster City, 
CA, USA) as follows: 95°C for 600 sec, 55°C for 120 sec and 72°C for 
120 sec, followed by 18 cycles with 95°C for 15 sec, 60°C for 240 sec, 
finally 600 sec at 99.9°C; and hold at 4°C.
Real-Time PCR
Real-Time PCR reactions (qRT- PCR) were performed using the 
high-throughput BioMark Real-Time PCR system (Fluidigm, South 
San Francisco, CA). PreAmplified cDNA samples were diluted with 
DNA Suspension buffer (Teknova, Hollister, CA, USA) 1:5 times. 
Four hundred ninety µl of TaqMan Universal PCR Master Mix, No 
AmpErase UNG, (Applied Biosystems, Foster City, CA, USA), and 49 
µl of 20x GE Sample Loading Reagent (Fluidigm, South San Francisco, 
CA) mixed and pipetted into a 96 well plate as 3.85 µl. One: 10 times 
diluted 3.15 µl of PreAmplified cDNA samples pipetted into each 
well and mixed. Then 5 µl of this mixture pipetted into sample inlets 
of a 96.96 Dynamic Arrays (Fluidigm, San Francisco, USA) 4.0 µl 1:1 
diluted 20X TaqMan miRNA Assays pipetted into assay inlets of a 96.96 
Dynamic array (Fluidigm). The BioMark IFC controller HX (Fluidigm, 
San Francisco, CA) was used to distribute the assay mix and sample mix 
from the loading inlets into the 96.96 Dynamic array reaction chambers 
for qRT-PCR by Fluidigm’s Integrated Fluidic Circuit Technology. Real-
Time PCR was performed by using BioMark System by using following 
protocol; Hold on at 95°C for 600 sec. and 95°C for 15 sec, 60°C for 60 
sec for 30 cycles. 
Statistical analysis
All statistical analyses were performed using the Biogazelle 
qbasePLUS 2.0 software. Mann-Whitney U test used and p<0.05 was 
considered statistically significant. Gene targets of miRNAs found to 
be up or down-regulated in patients with STEMI as compared with 
NSTEMI were predicted using the following algorithms: miRDB 
(miRDB.org) [13] and MirWalk (http://www.umm.uni-heidelberg.de/
apps/zmf/mirwalk) [14].
Results 
Patient demographics
As shown in Table 1, most participants with STEMI (N=9) were 
male (67%) and middle aged (58.4 ± 3.8 years). Participants presenting 
with NSTEMI in our cohort (N=4) were uniformly male and were 
slightly older (68.5 ± 5.3 years) than participants with STEMI. The 
majority of participants in both STEMI and NSTEMI groups had a 
history of hypertension (78% and 75%, respectively) and a minority had 
a history of diabetes (11% and 25%, respectively). All of the participants 
were Caucasian in race origin. A majority of the NSTEMI patients as 
compared to STEMI patients were receiving outpatient treatment with 
a statin, beta-blocker, ACE inhibitor, aspirin and clopidogrel prior to 
hospitalization. There were essentially no differences in the leukocyte, 
hemoglobin/hematocrit, and platelet counts between these two cohorts 
(Table 1). 
Cardiac catheterization results
The primary culprit lesion at the time of cardiac catheterization 
for 5 of the patients (all STEMI) was the mid-left anterior descending 
(LAD) coronary artery. The right coronary artery (RCA) was the culprit 
vessel in 3 patients (all STEMI). The obtuse marginal and 2nd diagonals 
were involved in 2 patients (NSTEMI) patients. The culprit lesion could 
not be determined in 2 patients with diffuse, three-vessel coronary 
disease, both NSTEMI (Table 2). An intracoronary (IC) thrombectomy 
was performed for documented thrombus in 9 patients. The peak 
troponin levels for STEMI and NSTEMI patients were 168.9 and 75.8 
(± SD needed), respectively (Table 2). 
MiRNAs in STEMI vs. NSTEMI: Plasma, Platelets, Peripheral 
Blood Mononuclear Cells (PBMCs)
In an effort to better understand differences between circulating 
miRNA profiles further stratified in patients with STEMI and NSTEMI, 
we found that expression of plasma miRNAs 92a-3p and 30d-5p, 
platelet miRNAs 186-5p and 342-3p, and PBMCs miRNAs 374b-5p 
were significantly lower in patients with STEMI as compared with 
NSTEMI (Figures 1A-1C). In contrast, plasma miRNAs 25-3p, and 
374b-5p, platelet miRNAs 25-3p and 221-3p, and PBMCs miRNAs 25-
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3p and 221-3p, were significantly higher in patients with STEMI than 
NSTEMI (Figures 1A-1C). 
In STEMI patients as compared to NSTEMI patients, there were 
distinct miRNAs identified, uniquely correlated to the subcomponents 
investigated. Namely, miRNA 25-3p was characterized associated 
with plasma, platelets, and PBMCs (Figure 2). However, miRNA 27a-
3p 146b-5p, and 221-3p were found in platelets and leukocytes only; 
miRNA 374-5p was identified in plasma and PBMCs only (Figure 2). 
STEMI MicroRNAs in Plasma, Platelets, and PBMCs
In the plasma of patients presenting with STEMI, the most 
downregulated miRNAs included 30d-5p and 30e-3p, yet the most 
upregulated miRNAs included 483-5p and 624-5p (Figure 3A). In the 
platelets of patients presenting with STEMI, the most downregulated 
miRNAs included 186-5p and 185-5p; miRNAs 127-3p and 221-3p were 
upregulated in this cellular subcomponent (Figure 3B). The PBMCs 
of patients presenting with STEMI demonstrated downregulation 
of miRNAs 93-3p and 574-3p; the most upregulated miRNAs in this 
subcomponent included 374a-5p and 27a-3p (Figure 3C). Common 
miRNAs in STEMI patients include 30d-5p in plasma, platelets, and 
PBMCs, 30e-3p between plasma and platelets, and 15b-5p, 25-3p and 
27a-3p between platelets and PBMCs (Figure 4).
NSTEMI MicroRNAs in Plasma, Platelets, and PBMCs
In the plasma of patients presenting with NSTEMI the most 
downregulated miRNAs included 624-5p and 324-5p; the most 
upregulated miRNAs included 483-5p (Figure 5A). In patients 
presenting with NSTEMI, the most downregulated miRNAs in platelets 
were 20a-5p and 942, while the most upregulated miRNAs included 
483-5p and 146a-5p (Figure 5B). In the PBMCs of patients presenting 
with NSTEMI, the most downregulated miRNAs included 19b-3p and 
15b-5p; the most upregulated miRNAs consisted of 29a-3p (Figure 5C). 
MiRNA 30d-5p was found in all of the subcomponents of NSTEMI 
patients. MiRNA 221-3p and 483-5p was associated with both the 
plasma and platelet subcomponents of NSTEMI patients; miRNA 
15b-5p, 16-5p, 30a-5p were common between platelets and PBMCs in 
NSTEMI patients (Figure 6). 
Discussion
In this exploratory analysis of 13 patients with ACS, we employed 
novel high-throughput methods to quantify expression of 343 miRNAs 
from distinct circulating blood pools. We found that 5 miRNAs were 
differentially expressed across plasma, platelets, and PBMCs in patients 
with NSTEMI and STEMI, including several miRNAs implicated in 
regulation of processes important to the pathogenesis of ACS [15-18]. 
MicroRNA profiles of patients with STEMI compared to 
NSTEMI 
MiRNAs 25-3p and 221-3p were both found upregulated in STEMI 
compared to NSTEMI patients (Figure 1 and 2). Of interest, previously 
identified validated targets for miRNA 25-3p and 221-3p include 
CDKN1C (or p57/kip2) [19]. CDKN1C, a cell cycle inhibitor, was 
previously found associated with apoptosis, transcriptional regulation, 
and cell migration [20]. Of interest, Galardi et al. determined 
knockdown of miRNA 221-3p via antisense LNA oligonucleotides in 
a prostate carcinoma model reduced clonogenicity in vitro, supporting 
the role of miRNA 221-3p inhibiting CDKN1C and subsequent G1/S 
cell cycle progression [21]. Therefore, a role of miRNA 25-3p and 221-
3p is possible in also activating CDK2 vis CDKN1C inhibition in the 
setting of STEMI, where cell proliferation is necessary in the milieu of 
acute myocyte damage and cell death [19]. 
Since it is well known multiple miRNAs may function at the 
same target, it is possible miRNA 25-3p and 221-3p are functioning 
in conjunction, both binding to the CDN1C 3’UTR to enhance 
CDK2 activation and cell cycle progression through the G2/S phase. 
Although cell activation and proliferation are necessary in the setting 
of myocyte death in the setting of STEMI, such mechanisms would also 
presumably be important in the setting of NSTEMI. How and why this 
mechanism is unique as compared to NSTEMI patients, which would 
also presumably require cell proliferation in the myocyte damage still 
needs to be elucidated. 
MiRNA 374b-5p was significantly up-regulated in plasma, yet 
down-regulated in PBMCs in patients with STEMI relative to patients 
with NSTEMI (Figure 1). Predictive miRNA target software suggests 
that the targets of miRNA 374b-5p include cell adhesion molecule 2 
(CAD2) and fibroblast growth factor 5 (FGF-5) [13]. Of note, CAD2 
has been implicated in coronary artery disease and patient death; FGF-
5 has been associated with ischemic heart disease, in vitro [15,16,22]. 
With the targets of miRNA 375-5p, namely CAD2 and FDF-5, being 
already demonstrated involved with heart disease, suggests a possible 
involvement of miR-374b-5p in myocardial infarction [15,16].
                  STEMI(N=9)
NSTEMI
(N=4)
Demographics:
Mean age (years) 58.4 ± 3.8 68.5 ± 5.33
Sex (Male) 6 (67) 4 (100)
Race-White 9 (100) 4(100)
Heart Rate (BPM) 84.9 ± 7.5 75.8 ± 11.7
Blood Pressure (SBP/DBP) 151 ± 10.5 / 91.6 ± 12.5 137.5 ± 4 / 81.3 ± 3.2
Troponin 59.6 ± 18.4 25.8 ± 16.8
Creatinine 1.1 ± 0.18 1.3 ± 0.35
Leukocytes 10.9 ± 1.1 10.7 ± 1.5
Platelets 220.8 ± 19.6 227.5 ± 22.6
Hematocrit 40.5 ± 1.8 39 ± 0.64
Hemoglobin 13.6 ± 0.6 12.8 ± 0.35
Body Mass Index (kg/m2), 
mean +/- SE 28.1 ± 0.8 26.2 ± 1.74
Comorbid conditions:
   Hypertension 7 (78) 3 (75)
   Coronary artery disease 4 (44) 2 (50)
   Diabetes Mellitus 1 (11) 1 (25)
   Dyslipidemia 4 (44) 4 (100)
   Current smoking 5 (56) 1 (25)
   Alcohol 2 (22) 1 (25)
Prior History PCI 4 (44) 2 (50)
Prior History CABG 0 (0) 1 (25)
Pre-Hospital Medications:
   Statins 2 (22) 4 (100)
   Beta blocker 1 (11) 2 (50)
Angiotensin-converting 
enzyme inhibitor / Angiotensin 
receptor blocker
3 (33) 2 (50)
   Calcium channel blocker 2 (22) 0 (0)
   Diuretics 2 (22) 0 (0)
   Aspirin 3 (33) 3 (75)
   Clopidogrel 1 (11) 3 (75)
   Nitroglycerin 3 (33) 2 (50)
ACE-I – Angiotensin Converting Enzyme Inhibitor; ARB – Angiotensin II Receptor 
Blocker
Table 1: Patient demographic characteristics
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STEMI only-plasma, platelets, and leukocytes 
In patients with STEMI, miRNA 30d-5p was downregulated in 
plasma and platelets, but upregulated in the PBMCs (Figure 3). Validated 
miRNA 30d-5p targets include G-protein alpha inhibiting activity 
polypeptide 2 (GNAI2) or Galphai2, an alpha subunit of G proteins 
involved in adenylate cyclase activation and intracellular signaling [23]. 
MiRNA 30d-5p was shown to bind GNAI2 in a hepatocellular carcinoma 
(HCC) via luciferase reporter assay technology, where miRNA 30d-
5p associated GAI2 knockdown increased HCC cell migration and 
invasion [24]. Of note, absence of Galphai2 has been shown associated 
with ventricular arrhythmias in a Galphai2 knockout mice model when 
challenged with programmed electrical stimulation. A potential role of 
miRNA 30d-5p, Galphai2, and STEMI is possible, but future studies 
would be needed to elucidate this possible relationship [25,26]. 
MiRNA 483-5p was found upregulated in plasma of STEMI 
patients (Figure 3A). Interestingly, miRNA 483-5p, transcribed from 
the intronic region of insulin-like growth factor-2, was recently found 
to inhibit angiogenesis, potentially by binding to serum response factor 
(SRF) [17]. Of note, overexpression of miRNA 483-5p was shown to 
inhibit angiogenesis, while inhibition of miRNA 483-5p can promote 
angiogenesis, both in vitro [17]. In addition, miRNA 483-5p was shown 
downregulated in human umbilical vein endothelial cells (HUVECS) 
cells under hypoxic conditions, again implicating a role in angiogenesis 
[17].
NSTEMI only-plasma, platelets, and PBMCs 
In addition to miRNA 30d-5p association in STEMI patients, it 
was also shown downregulated in the plasma, platelets, and PBMCs 
Subject  # ACS Type Location of Culprit Lesion
Intra-coronary thrombus 
documented
Single or Multi 
vessel Disease** EF (%)
Troponin 
(Initial)
Troponin 
(Peak)
Day of Cath relative to 
admission day (Day 0)
1 NSTEMI Obtuse Marginal Yes Single 50 0.65 75.80 0
2 STEMI RCA No Multi 65 22.83 73.50 0
3 STEMI RCA Yes Single 45 42.67 42.67 0
4 STEMI Mid LAD Yes Single 20 93.42 168.90 0
5 STEMI Mid LAD Yes Single 30 1.83 89.60 0
6 STEMI Proximal LAD Yes Single 30 0.06 16.85 0
7 STEMI Mid LAD Yes Single 45 0.82 108.86 0
8 NSTEMI Undetermined No Multi 35 0.01 13.96 1
9 NSTEMI Undetermined No Multi 20 2.88 4.3 1
10 STEMI Mid LAD Yes Single 35 1.66 8.47 0
11 STEMI Mid LAD Yes Single 25 0.04 19.24 0
12 STEMI Mid RCA Yes Multi 60 3.71 8.64 0
13 NSTEMI 2nd Diagonal Yes Single UTO 5.3 9.07 1
ACS – Acute Coronary Syndrome; IC – Intracoronary; EF – Ejection Fraction; NSTEMI – Non ST Segment Elevation Myocardial Infarction; STEMI – ST Segment Elevation 
Myocardial Infarction; RCA – Right Coronary Artery; LAD – Left Anterior Descending Coronary Artery; UTO – Unable To Obtain
Table 2: Patient cardiac catheterization results 
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Figure 1: MiRNA Levels in STEMI vs. NSTEMI: Plasma, Platelets, Peripheral Blood Mononuclear Cells (PBMCs).
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of NSTEMI patients (Figure 5). Although, miRNA 30d-5p can bind to 
alpha subunits of G-proteins [24], it has also been shown to bind to 
p53, a tumor suppressor gene involved in tumorigenesis and cell cycle 
progression [27]. MiRNA 30d-5p was shown to bind to the 3’UTR of 
the p53 transcript, thereby reducing p53 protein expression and the 
transcription of associated p53 related genes in a multiple myeloma 
model [28]. Conversely, inhibition of miRNA 30d-5p increased p53 
protein expression and corresponding expected apoptosis [28]. Of note, 
p53 is known to be involved in atherosclerotic plaque disruption, where 
overexpression of p53 in adenoviral constructs can induce plaque 
rupture in a rabbit model [18]. Therefore, the role of miRNA 30d-5p, 
p53, and possible role in NSTEMI is evident. 
In addition to being upregulated in STEMI compared to NSTEMI 
patients (Figure 1), miRNA 221-3p was also shown upregulated in 
plasma, but downregulated in platelets of NSTEMI patients (Figure 
5). Why miRNA 221-3p was downregulated in platelets of NSTEMI 
patients, yet the clinical significance is currently unclear. What has been 
demonstrated is miRNA 221-3p also has similar targets as miRNA 25-
3p, again including the cell cycle inhibitor CDKN1C. MiRNA 221-3p 
binding to CDKN1C, demonstrated in glioblastoma [29] and thyroid 
papillary carcinomas [30] cells, respectively, may also play a role in cell 
cycle progression in the setting of myocyte proliferation in the setting 
of myocardial ischemia. 
As previously mentioned, miRNA 483-5p was found upregulated 
in the plasma of STEMI patients compared to whole blood. MiRNA 
483-5p was also found up-regulated in both the plasma and platelets 
of NSTEMI patients (Figure 5A and 5B). To have miRNA 483-5p 
upregulated in the plasma of STEMI patients (Figure 3A), as well as 
in both the plasma and platelets in the NSTEMI patients (Figure 5A 
and 5B) is perplexing since angiogenesis would presumably be initiated 
in the setting of hypoxia. Possible explanations include additional 
targets and roles for 483-5p other than those related to angiogenesis. 
Also, with ischemia being a dynamic process and the timing of plasma 
procurement differing amongst patients, a more diverse role for miRNA 
483-5p may be possible. 
MiRNAs are rapidly emerging as biomarkers for acute myocardial 
infarction [22,31,32]. A study of 33 patients with acute STEMI found 
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Figure 2: Common miRNAs in STEMI vs. NSTEMI: Plasma, Platelets, Peripheral 
Blood Mononuclear Cells (PBMCs).
 
Plasma
Platelets Leukocytes
miR-624-5p
miR-483-5p
miR-30a-5p
miR-218-5p
miR-574-3p
miR-146-5p
miR-590a-5p
miR-29c-3p
miR-16-1-3p
miR-212b-3p
miR-140-3p
miR-532-3p
miR-16-5p
miR-93-3p
miR-15b-5p
miR-25-3p
miR-27a-3p
miR-27b-3p
miR-103a-3p
miR-145-5p
miR-185-5p
miR-186-5p
miR-221-3p
miR-374a-5p
miR-664-3p
miR-30e-3p
miR-30d-5p
miR-127-3p
miR-302c-3p
miR-31-5p
miR-423-5p
miR-19b-3p
miR-125a-5p
RNU44
miR-342-3p
miR-151a-5p
miR-505-5p
Figure 4:  STEMI patients: Common miRNAs in Plasma, Platelets, and 
Peripheral Blood Mononuclear Cells (PBMCs).
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Figure 3: STEMI MicroRNA Levels in Plasma, Platelets, and Peripheral Blood 
Mononuclear Cells (PBMCs). 
MicroRNA Target Gene Resultant Effects Ref
Mir-1 Hand 2 Reduction of ventricular myocytes; STEMI [38]
Mir-30c Increased CTGF Cardiac hypertrophy; STEMI [5]
Mir-126 Vascular endothelial growth factor (VEGF) Heart valve development [39]
Mir-133 Kv4-encoded fast potassium channel
QT prolongation; reduced 
myocardial fibrosis;  
STEMI
[40] 
Mir-208 Myh7 Cardiac remodeling; diastolic dysfunction [41]
Mir-320 Heat Shock Protein-20 Cardiac Ischemia/ Reperfusion Injury [34]
Mir-374-5p Cell Adhesion Molecule 2 Coronary Artery Disease [41], [43], [44]
Mir-483-5p Myomesin (MYOM2) Interconnects major sarcomere structure [27], [43]
Mir-574-3p Coiled-coil domain family 1 Myocardial infarction [41], [46]
Mir-499 Repressed histone deacetylase-4; Sox6
Enhanced cardiomyocyte 
differentiation; STEMI [42]
Mir-601 TPM3 Tropomyosin 3 [27]
Mir-1275 Synaptotagmin VII HUVEC cell shear stress [11], [41] 
Mir-1291 Matrix metallopeptidase-24 STEMI [5]
*Using MirWalk (http://www.ma.uni-heidelberg.de/apps/zmf/mirwalk/) [14] 
Mirdb (http://www.mirdb.org) [13]
Table 3: miRNAs Up or down-regulated in patients with an acute coronary 
syndrome and their target molecules*
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increased circulating plasma levels of miRNA 1, 133a, 133b, and 499-, 
and decreased levels of plasma miRNA 122 and 375 [31]. MiRNAs 1291 
and 663b have been used to discriminate patients with STEMIs from 
control cases with particularly high sensitivity, specificity and accuracy 
[6]. Myocyte specific miRNA 208b and 499 were detectable in patients 
with cardiac damage, including acute myocardial infarction [32]. 
MiRNA-21 has been associated with interstitial fibrosis and cardiac 
hypertrophy and miRNA-320 with cardiac ischemia and reperfusion 
injury, respectively [33,34]. MiRNA-133a and miRNA-208b are 
associated with increased risk of death in patients presenting with 
acute coronary syndrome [35]. Finally, miRNA-133a and miRNA-499 
have been shown released from the heart via trans coronary circulation 
in troponin-positive patients [36,37]. These miRNAs were not found 
either up or downregulated in our study. This may be due to differences 
in either the testing strategies employed, timing of samples obtained, or 
in the patient populations evaluated. Interestingly, as related to miRNA 
kinetics over time, Liebetrau et al. [38] recently determined increased 
circulating levels of mirR-1, miR-208a, and miR-133a over a 4 hour 
time frame after AMI induction [38]. Vogel et al. [39] revealed changes 
in miR 1915 and miR-181c over time in 18 troponin negative STEMI 
patients [39]. Both of these studies continue to support the ever growing 
body of literature supporting the role miRNAs as potential circulating 
biomarkers for myocardial damage [31,32,35]. Another advantage of 
employing miRNA as a circulating biomarker of AMI is phlebotimized 
blood draws are routine and with minimal adverse effects as compared 
to the increased risk of hemorrhage and sedation medication concerns 
as compared to coronary catheterization procedures. Finally and of 
note, literature has revealed difficulty in miRNA identification in 
patients treated with heparin previous to miRNA quantification; none 
of the patients in our study were treated with heparin prior to sample 
procurement [40]. 
Implications
This proposal represents a significant advance, demonstrating 
unique miRNA profiles between the plasma, platelets, and leukocytes 
across both STEMI and NSTEMI patients (Figure 2). Our findings have 
important implications since the miRNAs found to be upregulated both 
in participants with STEMI and NSTEMI, namely miR-25-3p, miR-
30d-5p, miR-221-3p, miR-374b-5p, and miR-483-5p) may be important 
to gene regulation across ACS subtypes. Our findings may also help to 
elucidate possible cross-talk occurring between plasma and cell types 
in the setting of ACS, also potentially uncovering potential therapeutic 
treatment targets. Our results may also be useful as additional miRNAs 
circulating biomarkers for ACS in addition to those already identified 
[35-39]. Our observation that miRNA profiles differ significantly across 
circulation subcomponents in the setting of ACS emphasize that future 
studies should consider subcomponent-specific miRNA expression 
analyses.
Limitations
We recognize that our small sample size limits generalizability 
given the complexity of miRNAs within the biological system in 
addition to the diverse genetic, social, and treatment characteristics of 
patients presenting with an ACS. We are also aware the differences in 
patient demographics may also have affect these study results. Future 
studies including larger and more diverse patient populations will be 
needed to validate our hypothesis-generating findings. We are also 
aware that it would be ideal to have better information about the timing 
of symptom onset relative to miRNA quantification. The specific time 
of this upregulation still needs to be further evaluated. Unfortunately, 
little information is available with respect to pre-hospital delay in 
presentation or duration of symptoms, limiting our ability to precisely 
identify miRNA dysregulation with respect to symptom onset Future 
studies will include evaluating circulating miRNA profiles in well-
defined patient populations and at different time points during the 
peri-infarct period as well as miRNA profiles associated with unstable 
angina and non-ACS associated causes of chest pain, such as GERD. 
Conclusion
This investigation reveals unique miRNA profiles in plasma, platelets, 
and PBMCs of STEMI and NSTEMI patients, including miRNA 25-3p, 
30d-5p, 221-3p, 374b-5p, and 483-5p. This novel discovery suggests 
both that there may by unique, circulating subcomponent miRNAs 
that may allow for future differentiation of patients presenting with an 
ACS. We anticipate in future studies with larger numbers of patients, 
concomitant changes in other ACS associated miRNAs, including 
miRNA-1, miRNA-133, and miRNA-208, 483-5p and 601 in the 
setting of STEMI and NSTEMI (Table 3) [5,31,32]. We also anticipate 
future research will reveal unique miRNA profiles in circulating 
subcomponents of other aspects of an ACS, namely UA, in addition to 
non-ACS causes of chest pain. 
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Figure 5: NSTEMI MicroRNA Levels in Plasma, Platelets, and Peripheral Blood 
Mononuclear Cells (PBMCs). 
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